BR112015013123A2 - inibidores de beta-lactamase - Google Patents

inibidores de beta-lactamase

Info

Publication number
BR112015013123A2
BR112015013123A2 BR112015013123A BR112015013123A BR112015013123A2 BR 112015013123 A2 BR112015013123 A2 BR 112015013123A2 BR 112015013123 A BR112015013123 A BR 112015013123A BR 112015013123 A BR112015013123 A BR 112015013123A BR 112015013123 A2 BR112015013123 A2 BR 112015013123A2
Authority
BR
Brazil
Prior art keywords
beta
lactamase
compounds
lactamase inhibitors
compounds described
Prior art date
Application number
BR112015013123A
Other languages
English (en)
Other versions
BR112015013123B1 (pt
Inventor
Liu Bin
J Burns Christopher
C Pevear Daniel
Mcgarry Daniel
Daigle Denis
e lee trout Robert
Original Assignee
Venatorx Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Venatorx Pharmaceuticals Inc filed Critical Venatorx Pharmaceuticals Inc
Publication of BR112015013123A2 publication Critical patent/BR112015013123A2/pt
Publication of BR112015013123B1 publication Critical patent/BR112015013123B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)

Abstract

beta-lactamase inhibitors abstract of the disclosure described herein are compounds and compositions that modulate the activity of beta-lactamases. in some embodiments, the compounds described herein inhibit beta-lactamase. in certain embodiments, the compounds described herein are useful in the treatment of bacterial infections. ______________________________________________________________________ resumo patente de invenção: "inibidores de beta-lactamase". são aqui descritos compostos e composições que modulam a atividade das beta-lactamases. em algumas formas de realização, os compostos aqui descritos inibem a beta-lactamase. em certas formas de realização os compostos aqui descritos são úteis no tratamento de infecções bacterianas.
BR112015013123-9A 2012-12-07 2013-12-05 inibidores de beta-lactamase, seu uso, e composição farmacêutica BR112015013123B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261734900P 2012-12-07 2012-12-07
US61/734,900 2012-12-07
US201361783238P 2013-03-14 2013-03-14
US61/783,238 2013-03-14
PCT/US2013/073428 WO2014089365A1 (en) 2012-12-07 2013-12-05 Beta-lactamase inhibitors

Publications (2)

Publication Number Publication Date
BR112015013123A2 true BR112015013123A2 (pt) 2017-07-11
BR112015013123B1 BR112015013123B1 (pt) 2021-02-17

Family

ID=50884012

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015013123-9A BR112015013123B1 (pt) 2012-12-07 2013-12-05 inibidores de beta-lactamase, seu uso, e composição farmacêutica

Country Status (17)

Country Link
US (5) US9422314B2 (pt)
EP (2) EP3922635A1 (pt)
JP (2) JP6403219B2 (pt)
KR (1) KR102147420B1 (pt)
CN (1) CN105026407B (pt)
AU (1) AU2013355110B2 (pt)
BR (1) BR112015013123B1 (pt)
CA (1) CA2893943C (pt)
ES (1) ES2878118T3 (pt)
HK (1) HK1217334A1 (pt)
HR (1) HRP20210879T1 (pt)
IL (1) IL239212B (pt)
PL (1) PL2928898T3 (pt)
PT (1) PT2928898T (pt)
RU (1) RU2654692C2 (pt)
WO (1) WO2014089365A1 (pt)
ZA (1) ZA201504200B (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS60310B1 (sr) 2010-08-10 2020-07-31 Rempex Pharmaceuticals Inc Ciklični derivati estra boronske kiseline, postupak za pripremu injihove terapeutske upotrebe
US9012491B2 (en) 2011-08-31 2015-04-21 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
CA2893943C (en) * 2012-12-07 2021-03-02 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
EP2941247A4 (en) 2013-01-04 2017-02-08 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9642869B2 (en) * 2013-01-04 2017-05-09 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CN105101970B (zh) 2013-01-10 2018-11-20 维纳拓尔斯制药公司 β-内酰胺酶抑制剂
EP2970340B1 (en) 2013-03-14 2020-02-12 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
EP3139930A4 (en) 2014-05-05 2018-01-17 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
HUE046836T2 (hu) 2014-05-05 2020-03-30 Rempex Pharmaceuticals Inc Boronát sók szintézise és alkalmazásuk
CN106459096B (zh) 2014-05-19 2019-03-08 莱姆派克斯制药公司 硼酸衍生物及其治疗用途
US9511142B2 (en) 2014-06-11 2016-12-06 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US20150361108A1 (en) * 2014-06-11 2015-12-17 VenatoRx Pharmaceuticals, Inc. Orally bioavailable beta-lactamase inhibitors
RU2686740C2 (ru) 2014-06-11 2019-04-30 Венаторкс Фармасьютикалс, Инк. Ингибиторы бета-лактамазы
EA201692301A1 (ru) * 2014-07-01 2017-06-30 Ремпекс Фармасьютикалз, Инк. Производные бороновой кислоты и их терапевтическое применение
WO2016081297A1 (en) 2014-11-18 2016-05-26 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
CN107207537B (zh) 2014-12-19 2019-05-31 莱姆派克斯制药公司 用于生产硼酸衍生物的设备和连续流方法
CA2971763A1 (en) * 2014-12-23 2016-06-30 Bergenbio Asa Inhibitors of akt kinase
US20180051041A1 (en) 2015-03-17 2018-02-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US10399996B2 (en) 2015-09-11 2019-09-03 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2017100537A1 (en) 2015-12-10 2017-06-15 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
CN105801610B (zh) * 2016-04-19 2018-05-18 武汉维舜医药科技有限公司 新型广谱β-内酰胺酶抑制剂
EP3478693B1 (en) * 2016-06-30 2021-07-21 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
US10889600B2 (en) 2016-08-04 2021-01-12 VenatoRx Pharmaceuticals, Inc. Boron-containing compounds
GB201613946D0 (en) * 2016-08-15 2016-09-28 Univ Oslo Compounds
MY196966A (en) 2017-03-06 2023-05-15 Everest Medicines Singapore Pte Ltd Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof
TW201841642A (zh) * 2017-04-28 2018-12-01 日商大日本住友製藥股份有限公司 雜環衍生物
GB201708002D0 (en) 2017-05-18 2017-07-05 Univ Oxford Innovation Ltd ß-Lactamase inhibitors
EP3630783A4 (en) 2017-05-26 2021-03-03 Venatorx Pharmaceuticals, Inc. PENICILLIN BINDING PROTEIN INHIBITORS
EP3630782A4 (en) * 2017-05-26 2021-03-03 Venatorx Pharmaceuticals, Inc. PENICILLIN BINDING PROTEIN INHIBITORS
IL273551B2 (en) 2017-10-11 2024-02-01 Qpex Biopharma Inc Boronic acid derivatives and their synthesis
JOP20200101A1 (ar) * 2017-11-01 2022-10-30 Melinta Therapeutics Inc تخليق مشتقات إستر بورونات واستخداماتها
US11702431B2 (en) 2018-04-27 2023-07-18 Sumitomo Pharma Co., Ltd. Oxo-substituted compound
EP3802551A4 (en) * 2018-05-25 2022-03-02 Venatorx Pharmaceuticals, Inc. PENICILLIN-BINDING PROTEIN INHIBITORS
EP3849562A4 (en) * 2018-09-12 2022-05-18 Venatorx Pharmaceuticals, Inc. COMPOSITIONS IN THE FORM OF COMBINATIONS COMPRISING A BETA-LACTAMASE INHIBITOR
AU2020256179A1 (en) * 2019-04-02 2021-11-18 VenatoRx Pharmaceuticals, Inc. Solid forms of an orally-delivered beta-lactamase inhibitor and uses thereof
KR20220088736A (ko) 2019-10-25 2022-06-28 스미토모 파마 가부시키가이샤 신규 치환 축환형 화합물
US11058695B2 (en) * 2019-11-08 2021-07-13 Myongji University Industry And Academia Cooperation Foundation Inhibitor of carbapenem-hydrolyzing class D beta-lactamases
EP4201942A1 (en) 2020-08-20 2023-06-28 Phaeno Therapeutics Co., Ltd. Boracic acid compound
TW202228720A (zh) * 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法
EP4301466A1 (en) * 2021-03-02 2024-01-10 Case Western Reserve University B-lactamase inhibitors and uses thereof
BR112023017203A2 (pt) 2021-04-13 2023-11-07 Tuojie Biotech Shanghai Co Ltd Derivado de ácido bórico que age como inibidor de beta-lactamase
WO2023155869A1 (zh) * 2022-02-18 2023-08-24 辉诺生物医药科技（杭州）有限公司 新的硼酸类化合物的晶型及其制备方法

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE41109B1 (en) 1974-04-20 1979-10-24 Beecham Group Ltd Novel -lactam antibiotic from streptomyces clavuligerus
IT1283467B1 (it) * 1996-07-19 1998-04-21 Menarini Farma Ind Derivati di cicloalcani 1,2 sostituiti come inibitori della trombina, procedimento per la loro preparazione e loro impiego in formulazioni
CA2385747A1 (en) 1999-09-17 2001-03-22 Gavin C. Hirst Pyrazolopyrimidines as therapeutic agents
US7271186B1 (en) * 2002-12-09 2007-09-18 Northwestern University Nanomolar β-lactamase inhibitors
AU2004256841A1 (en) 2003-06-10 2005-01-20 Fulcrum Pharmaceuticals, Inc. Beta-lactamase inhibitors and methods of use thereof
EA012927B1 (ru) 2004-03-30 2010-02-26 Миллениум Фармасьютикалз, Инк. Синтез эфиров бороновой кислоты и кислотных соединений
CN1965838A (zh) 2005-11-17 2007-05-23 李海超 含头孢匹胺和β－内酰胺酶抑制剂的药物组合物
US8901293B2 (en) 2005-12-07 2014-12-02 Basilea Pharmaceutica Ag Useful combinations of monobactam antibiotics with beta-lactamase inhibitors
CN101129382B (zh) 2006-08-25 2013-12-25 天津和美生物技术有限公司 含β-内酰胺类抗生素和缓冲组分的抗生素复方
JP2011504468A (ja) 2007-11-13 2011-02-10 プロテズ・ファーマシューティカルズ・インコーポレイテッド β−ラクタマーゼ阻害剤
US20100120715A1 (en) 2007-11-13 2010-05-13 Burns Christopher J Beta-lactamase inhibitors
RU2445314C9 (ru) 2008-01-18 2013-04-10 Мерк Шарп Энд Домэ Корп. Ингибиторы бета-лактамаз
AR076667A1 (es) 2009-05-12 2011-06-29 Novartis Int Pharm Ltd Inhibidores de beta-lactamasa
JP2013500974A (ja) 2009-07-28 2013-01-10 アナコール ファーマシューティカルズ，インコーポレイテッド 三置換ホウ素含有分子
RS60310B1 (sr) * 2010-08-10 2020-07-31 Rempex Pharmaceuticals Inc Ciklični derivati estra boronske kiseline, postupak za pripremu injihove terapeutske upotrebe
WO2013014497A1 (en) 2011-07-26 2013-01-31 Wockhardt Limited Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor
CN106146649B (zh) 2011-09-04 2020-09-01 株式会社糖锁工学研究所 附加糖链的多肽和含有该多肽的医药组合物
WO2013053372A1 (en) 2011-10-13 2013-04-18 Therabor Pharmaceuticals Boronic acid inhibitors of beta-lactamases
KR101288157B1 (ko) 2011-12-07 2013-07-19 백병하 기존 세파계 항생제 및 베타 락타마제 저해제로 배합된 내성균주에 기인한 감염증의 치료 및 예방을 위한 복합항생제
SG11201403254QA (en) 2011-12-22 2014-07-30 Ares Trading Sa Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors
WO2013122888A2 (en) 2012-02-15 2013-08-22 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
US9464098B2 (en) 2012-12-03 2016-10-11 Hoffmann-La Roche Inc. Substituted triazole boronic acid compounds
CA2893943C (en) * 2012-12-07 2021-03-02 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9642869B2 (en) 2013-01-04 2017-05-09 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
EP2941247A4 (en) 2013-01-04 2017-02-08 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CN105101970B (zh) * 2013-01-10 2018-11-20 维纳拓尔斯制药公司 β-内酰胺酶抑制剂
EP2970340B1 (en) 2013-03-14 2020-02-12 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US9120796B2 (en) 2013-10-02 2015-09-01 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
WO2015157618A1 (en) 2014-04-11 2015-10-15 The Texas A&M University System Novel inhibitors of the new delhi metallo beta lactamase (ndm-1)
CN106459096B (zh) 2014-05-19 2019-03-08 莱姆派克斯制药公司 硼酸衍生物及其治疗用途
RU2686740C2 (ru) * 2014-06-11 2019-04-30 Венаторкс Фармасьютикалс, Инк. Ингибиторы бета-лактамазы
US20150361108A1 (en) 2014-06-11 2015-12-17 VenatoRx Pharmaceuticals, Inc. Orally bioavailable beta-lactamase inhibitors
US9511142B2 (en) 2014-06-11 2016-12-06 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US20150361107A1 (en) * 2014-06-11 2015-12-17 VenatoRx Pharmaceuticals, Inc. Orally bioavailable beta-lactamase inhibitors
US9949982B2 (en) 2014-09-04 2018-04-24 Shionogi & Co., Ltd. Preparation containing cephalosporin having a catechol moiety
CN107207537B (zh) 2014-12-19 2019-05-31 莱姆派克斯制药公司 用于生产硼酸衍生物的设备和连续流方法
US10399996B2 (en) 2015-09-11 2019-09-03 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2017100537A1 (en) 2015-12-10 2017-06-15 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
CN105801610B (zh) 2016-04-19 2018-05-18 武汉维舜医药科技有限公司 新型广谱β-内酰胺酶抑制剂
US10889600B2 (en) 2016-08-04 2021-01-12 VenatoRx Pharmaceuticals, Inc. Boron-containing compounds
MY196966A (en) 2017-03-06 2023-05-15 Everest Medicines Singapore Pte Ltd Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof
EP3630782A4 (en) 2017-05-26 2021-03-03 Venatorx Pharmaceuticals, Inc. PENICILLIN BINDING PROTEIN INHIBITORS
EP3630783A4 (en) 2017-05-26 2021-03-03 Venatorx Pharmaceuticals, Inc. PENICILLIN BINDING PROTEIN INHIBITORS
WO2019118358A1 (en) 2017-12-11 2019-06-20 VenatoRx Pharmaceuticals, Inc. Hepatitis b capsid assembly modulators
EP3802551A4 (en) 2018-05-25 2022-03-02 Venatorx Pharmaceuticals, Inc. PENICILLIN-BINDING PROTEIN INHIBITORS

Also Published As

Publication number Publication date
AU2013355110B2 (en) 2017-11-09
EP2928898B1 (en) 2021-04-14
WO2014089365A1 (en) 2014-06-12
CA2893943A1 (en) 2014-06-12
US8912169B2 (en) 2014-12-16
US20180194783A1 (en) 2018-07-12
RU2654692C2 (ru) 2018-05-22
IL239212A0 (en) 2015-07-30
CN105026407B (zh) 2017-09-08
PT2928898T (pt) 2021-07-05
US10669290B2 (en) 2020-06-02
US10214547B2 (en) 2019-02-26
JP2018184409A (ja) 2018-11-22
EP2928898A4 (en) 2016-06-29
PL2928898T3 (pl) 2021-10-25
KR20150109348A (ko) 2015-10-01
RU2015126912A (ru) 2017-01-12
JP6403219B2 (ja) 2018-10-10
CA2893943C (en) 2021-03-02
EP2928898A1 (en) 2015-10-14
AU2013355110A1 (en) 2015-07-02
US20190225628A1 (en) 2019-07-25
ZA201504200B (en) 2017-09-27
CN105026407A (zh) 2015-11-04
IL239212B (en) 2019-10-31
ES2878118T3 (es) 2021-11-18
US9828391B2 (en) 2017-11-28
US20140171390A1 (en) 2014-06-19
US20150291630A1 (en) 2015-10-15
HRP20210879T1 (hr) 2021-08-20
KR102147420B1 (ko) 2020-08-25
US9422314B2 (en) 2016-08-23
US20160326189A1 (en) 2016-11-10
JP2016502973A (ja) 2016-02-01
EP3922635A1 (en) 2021-12-15
BR112015013123B1 (pt) 2021-02-17
HK1217334A1 (zh) 2017-01-06

Similar Documents

Publication Publication Date Title
BR112015013123A2 (pt) inibidores de beta-lactamase
PH12017501306A1 (en) Inhibitors of histone demethylases
AU2015205914B2 (en) 1,6- diazabicyclo [3,2,1] octan- 7- one derivatives and their use in the treatment of bacterial infections
EA201591743A1 (ru) СТИМУЛЯТОРЫ sGC
UA107423C2 (en) Fluoro-pyridinone derivatives useful as antibacterial agents
EA201270803A1 (ru) Тиоацетатные соединения, композиции на их основе и способы их применения
CY1122805T1 (el) Ενωσεις και μεθοδοι για την αγωγη βακτηριακων λοιμωξεων
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
EA201400990A1 (ru) Ингибиторы диацилглицеринацилтрансферазы 2
MX338610B (es) Composiciones farmaceuticas que comprenden sulbactam e inhibidor de beta-lactamasa.
MX2017012545A (es) Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
TR201905233T4 (tr) Dirençli bakteriyel enfeksiyonların tedavisine yönelik kombinasyon tedavisi.
WO2019040106A3 (en) COMPOUNDS, RELATED SALTS AND METHODS FOR THE TREATMENT OF DISEASES
BR112015023439A2 (pt) combinação de tratamentos de câncer utilizando micrornas e inibidores egfr-tki
MX2015016319A (es) Terapia de combinacion que comprende oxazolidinona-quinolonas para uso en el tratamiento de infecciones bacterianas.
PH12016500140A1 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
RS53466B (en) USE OF AMISULPRID FOR THE TREATMENT OF POSTOPERATIVE Nausea and Vomiting
BR112015018360A2 (pt) terapia de combinação para o tratamento de pneumonia nosocomial
TR201901348T4 (tr) Metap-2 inhibitörleri olarak pirolidinon türevleri.
MY178390A (en) Inhibitors of iap
ZA202006612B (en) Antibacterial compounds
MX2014010940A (es) El uso de antitrombina en el tratamiento de preeclampsia.
MX343517B (es) 2,4 pirimidinadiaminas sustituidas para su uso en lupus discoide.
EA201590347A1 (ru) Азагетероциклы в качестве ингибиторов bir2 и/или bir3
IN2013MU03216A (pt)

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/12/2013, OBSERVADAS AS CONDICOES LEGAIS.